These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 15169827)

  • 1. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells.
    Jones DC; Lau SS; Monks TJ
    J Pharmacol Exp Ther; 2004 Oct; 311(1):298-306. PubMed ID: 15169827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats.
    Miller RT; Lau SS; Monks TJ
    Chem Res Toxicol; 1996 Mar; 9(2):457-65. PubMed ID: 8839050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells.
    Carvalho M; Hawksworth G; Milhazes N; Borges F; Monks TJ; Fernandes E; Carvalho F; Bastos ML
    Arch Toxicol; 2002 Oct; 76(10):581-8. PubMed ID: 12373454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity.
    Bai F; Lau SS; Monks TJ
    Chem Res Toxicol; 1999 Dec; 12(12):1150-7. PubMed ID: 10604863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotoxicity mechanisms of thioether ecstasy metabolites.
    Capela JP; Macedo C; Branco PS; Ferreira LM; Lobo AM; Fernandes E; Remião F; Bastos ML; Dirnagl U; Meisel A; Carvalho F
    Neuroscience; 2007 Jun; 146(4):1743-57. PubMed ID: 17467183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic neurotoxicity of 3,4-(+/-)-methylenedioxyamphetamine and 3,4-(+/-)-methylendioxymethamphetamine (ecstasy) is potentiated by inhibition of gamma-glutamyl transpeptidase.
    Bai F; Jones DC; Lau SS; Monks TJ
    Chem Res Toxicol; 2001 Jul; 14(7):863-70. PubMed ID: 11453733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro.
    Carvalho M; Remião F; Milhazes N; Borges F; Fernandes E; Monteiro Mdo C; Gonçalves MJ; Seabra V; Amado F; Carvalho F; Bastos ML
    Chem Res Toxicol; 2004 May; 17(5):623-32. PubMed ID: 15144219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of metabolism in 3,4-(+)-methylenedioxyamphetamine and 3,4-(+)-methylenedioxymethamphetamine (ecstasy) toxicity.
    Monks TJ; Jones DC; Bai F; Lau SS
    Ther Drug Monit; 2004 Apr; 26(2):132-6. PubMed ID: 15228153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia.
    Capela JP; Meisel A; Abreu AR; Branco PS; Ferreira LM; Lobo AM; Remião F; Bastos ML; Carvalho F
    J Pharmacol Exp Ther; 2006 Jan; 316(1):53-61. PubMed ID: 16183702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacterial plate assays and electrochemical methods: an efficient tandem for evaluating the ability of catechol-thioether metabolites of MDMA ("ecstasy") to induce toxic effects through redox-cycling.
    Felim A; Urios A; Neudörffer A; Herrera G; Blanco M; Largeron M
    Chem Res Toxicol; 2007 Apr; 20(4):685-93. PubMed ID: 17355154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates.
    Carvalho M; Milhazes N; Remião F; Borges F; Fernandes E; Amado F; Monks TJ; Carvalho F; Bastos ML
    Arch Toxicol; 2004 Jan; 78(1):16-24. PubMed ID: 14586543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymethamphetamine in rat brain.
    Erives GV; Lau SS; Monks TJ
    J Pharmacol Exp Ther; 2008 Jan; 324(1):284-91. PubMed ID: 17906065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.
    Jones DC; Duvauchelle C; Ikegami A; Olsen CM; Lau SS; de la Torre R; Monks TJ
    J Pharmacol Exp Ther; 2005 Apr; 313(1):422-31. PubMed ID: 15634943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative neurochemical profile of 3,4-methylenedioxymethamphetamine and its metabolite alpha-methyldopamine on key targets of MDMA neurotoxicity.
    Escubedo E; Abad S; Torres I; Camarasa J; Pubill D
    Neurochem Int; 2011 Jan; 58(1):92-101. PubMed ID: 21074589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells.
    Ferreira PS; Nogueira TB; Costa VM; Branco PS; Ferreira LM; Fernandes E; Bastos ML; Meisel A; Carvalho F; Capela JP
    Toxicol Lett; 2013 Feb; 216(2-3):159-70. PubMed ID: 23194825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.
    Bankson MG; Cunningham KA
    J Pharmacol Exp Ther; 2001 Jun; 297(3):846-52. PubMed ID: 11356903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain.
    Darvesh AS; Yamamoto BK; Gudelsky GA
    J Pharmacol Exp Ther; 2005 Feb; 312(2):694-701. PubMed ID: 15456837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters.
    Schuldiner S; Steiner-Mordoch S; Yelin R; Wall SC; Rudnick G
    Mol Pharmacol; 1993 Dec; 44(6):1227-31. PubMed ID: 7903417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2,5-Bis-(glutathion-S-yl)-alpha-methyldopamine, a putative metabolite of (+/-)-3,4-methylenedioxyamphetamine, decreases brain serotonin concentrations.
    Miller RT; Lau SS; Monks TJ
    Eur J Pharmacol; 1997 Apr; 323(2-3):173-80. PubMed ID: 9128836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations.
    Bowyer JF; Young JF; Slikker W; Itzak Y; Mayorga AJ; Newport GD; Ali SF; Frederick DL; Paule MG
    Neurotoxicology; 2003 Jun; 24(3):379-90. PubMed ID: 12782103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.